Molecular and Clinical Insights in the Increasing Detection of BCR::ABL1 p190+ in Adult Acute Myeloid Leukemia Patients.

Autor:	DE Pinho Pessoa FMC; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., Nogueira BMD; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., Machado CB; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., Barreto IV; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., DA Costa Machado AK; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., Gadelha RB; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., DE Sousa Oliveira D; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil., Ribeiro RM; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil., Silva FAC; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil., Gurgel LA; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil., Medeiros JC; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil., DA Rocha Maciel A; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil., Lopes GS; Department of Hematology, César Cals General Hospital, Fortaleza, CE, Brazil., Vieira RPG; Department of Hematology, São Vicente de Paulo Maternity Hospital, Barbalha, CE, Brazil., DE Moraes Filho MO; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., DE Moraes MEA; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil., Khayat AS; Department of Biological Sciences, Oncology Research Center, Federal University of Pará, Belém, PA, Brazil., Moreira-Nunes CA; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil; carolfam@gmail.com.; Department of Biological Sciences, Oncology Research Center, Federal University of Pará, Belém, PA, Brazil.; Clementino Fraga Group, Central Unity, Molecular Biology Laboratory, Fortaleza, CE, Brazil.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2024 Jul-Aug; Vol. 38 (4), pp. 2016-2023.
DOI:	10.21873/invivo.13659
Abstrakt:	Background/aim: Acute myeloid leukemia (AML) is a myeloproliferative neoplasm marked by abnormal clonal expansion of hematopoietic progenitor cells, displaying karyotypic aberrations and genetic mutations as prognostic indicators. The World Health Organization (WHO) and the European LeukemiaNet guidelines categorize BCR::ABL1 p190+ AML as high risk. This study explored the identification of the increased incidence of BCR::ABL1 p190+ in our AML population. Patients and Methods: This study included 96 AML patients stratified according to WHO guidelines. Subsequently, patients were screened for genetic abnormalities, such as BCR::ABL1 p 190+, PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11 by quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis. Results: Among 96 AML patients, 36 displayed BCR::ABL1 p190+, overcoming the expected global incidence. Age variations (19 to 78 years) showed no significant laboratory differences between BCR::ABL1 p190+ and non-BCR::ABL p190+ cases. The overall survival analysis revealed no statistically significant differences among the patients (p=0.786). Conclusion: The analyzed population presented a higher frequency of BCR::ABL1 p190+ detection in adult AML patients when compared to what is described in the worldwide literature. Therefore, more studies are needed to establish the reason why this incidence is higher and what the best treatment approach should be in these cases. (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu